Deprenyl treatment attenuates long-term pre- and post-synaptic changes evoked by chronic methamphetamine

European Journal of Pharmacology

Volumn 573, Issue 1-3, 2007, Pages 100-110

  Davidson, Colin ^a   Chen, Qiang ^a   Zhang, Xiuwn ^a   Xiong, Xueying ^a   Lazarus, Cindy ^a   Lee, Tong H ^a   Ellinwood, Everett H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Accumbens; Caudate; Dopamine; GluR1; NR2B; Prefrontal cortex

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DOPAMINE; GLUTAMATE RECEPTOR 1; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG MECHANISM; DRUG MEGADOSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LONG TERM CARE; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; POSTSYNAPTIC MEMBRANE; PREFRONTAL CORTEX; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SYNAPTIC TRANSMISSION; WESTERN BLOTTING;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTIPARKINSON AGENTS; BLOTTING, WESTERN; BODY WEIGHT; CAUDATE NUCLEUS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOCHEMISTRY; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SUBCUTANEOUS; MALE; MESENCEPHALON; METHAMPHETAMINE; PHOSPHORYLATION; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; SELEGILINE; SUBSTANTIA NIGRA; SYNAPSES; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 34648844241     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.06.046     Document Type: Article

References (87)

1. Ahlemeyer B., Kolker S., Zhu Y., Hoffmann G.F., and Krieglstein J. Increase in glutamate induced neurotoxicity by activated astrocytes involves stimulation of protein kinase C. J. Neurochem. 82 (2002) 504-515
2. Arnsten A.F.T., and Li B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol. Psychiatry 57 (2005) 1377-1384
3. Arundine M., and Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 34 (2003) 325-337
4. Askew B.M. Hyperpyrexia as a contributing factor in the toxicity of amphetamine in aggregated mice. Br. J. Pharmacol 19 (1962) 245-257
5. Bartzokis G., Beckson M., Newton T., Mandelkern M., Mintz J., Foster J.A., Ling W., and Bridge T.P. Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology 20 (1999) 582-590
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
7. Broening H.W., Pu C., and Vorhees C.V. Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell. Synapse 27 (1997) 153-160
8. Cappon G.D., Morford L.L., and Vorhees C.V. Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response. Dev. Brain Res. 103 (1997) 155-162
9. Chazot P.L. CP-101606 Pfizer Inc. Curr. Opin. Investig. Drugs 1 (2000) 370-374
10. Chen N., Luo T., Wellington C., Metzler M., McCutcheon K., Hayden M.R., and Raymond L.A. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem. 72 (1999) 1890-1898
11. Cho A.K., Melega W.P., Kuczenski R., and Segal D.S. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39 (2001) 161-166
12. Dave J.R., Williams A.J., Moffett J.R., Koenig M.L., and Tortella F.C. Studies on neuronal apoptosis in primary forebrain cultures: neuroprotective/anti-apoptotic action of NR2B NMDA antagonists. Neurotox. Res. 5 (2003) 255-264
13. Davidson C., Gow A.J., Lee T.H., and Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brains Res. Rev. 36 (2001) 1-22
14. Davidson C., Lee T.H., and Ellinwood E.H. Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem. Int. 46 (2005) 189-203
15. Derkach V., Barria A., and Soderling T.R. Ca2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3269-3274
16. Fitzgerald L.W., Ortiz J., Hamedani A.G., and Nestler E.J. Drugs of abuse and stress increase the expression of gluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptation among cross-sensitizing agents. J. Neurosci. 16 (1996) 274-282
17. Gappoeva M.U., Izykenova G.A., Granstrem O.K., and Dambinova S.A. Expression of NMDA neuroreceptors in experimental ischemia. Biochem. Russ. 68 (2003) 696-702
18. Gerdeman G.L., Partridge J.G., Lupica C.R., and Lovinger D.M. It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci. 26 (2003) 184-192
19. Haberny K.A., Walsh S.L., Ginn D.H., Wilkins J.N., Garner J.E., Setoda D., and Bigelow G.E. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend. 39 (1995) 55-62
20. Harris B.R., Gibson D.A., Prendergast M.A., Blanchard J.A., Holley R.C., Hart S.R., Scotland R.L., Foster T.C., Pedigo N.W., and Littleton J.M. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-d-aspartate receptors. Alcohol., Clin. Exp. Res. 27 (2003) 1724-1735
21. Haughey N.J., Nath A., Mattson M.P., Slevin J.T., and Geiger J.D. HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J. Neurochem. 78 (2001) 457-767
22. Hemby S.E., Horman B., and Tang W. Differential regulation of ionotropic glutamate receptor subunits following cocaine self-administration. Brain Res. 1064 (2005) 75-82
23. Higuchi H., Kamata M., Sugawara Y., and Yoshida K. Remarkable effect of selegiline (l-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report. Clin. Neuropharmacol. 28 (2005) 191-192
24. Houtsmuller E.J., Notes L.D., Newton T., van Sluis N., Chiang N., Elkashef A., and Bigelow G.E. Transdermal selegeline and intravenous cocaine: safety and interactions. Psychopharmacology 172 (2004) 31-40
25. Ilani T., Lamensdorf I., and Finberg J.P. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig. Br. J. Pharmacol. 130 (2000) 1992-1998
26. Kalivas P.W., Volkow N., and Seamans J. Unmanageable motivation in addiction: a path in prefrontal-accumbens glutamate transport. Neuron 45 (2005) 647-650
27. Kim D.Y., Kim S.H., Choi H.B., Min C., and Gwag B.J. High abundance of mGlu1 receptor mRNA and reduced Q/R editing of GluR2 mRNA in individual NADPH-diaphorase neurons. Mol. Cell. Neurosci. 17 (2001) 1025-1033
28. Kitani K., Minami C., Isobe K., Maehara K., Kanai S., Ivy G.O., and Carrillo M.C. Why (-) deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech. Ageing Develop. 123 (2002) 1087-1100
29. Knoll J. The pharmacology of selegiline ((-)deprenyl). New aspects. Acta. Neurol. Scand., Suppl. 126 (1989) 83-91
30. Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol. Toxicol. 82 (1998) 57-66
31. Knoll J., and Miklya I. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch. Int. Pharmacodyn. Ther. 328 (1994) 1-15
32. Kolker S., Okun J.G., Ahlemeyer B., Wyse A.T., Horster F., Wajner M., Kohlmuller D., Mayatepek E., Krieglstein J., and Hoffmann G.F. Chronic treatment with glutaric acid induces partial tolerance to excitotoxicity in neuronal cultures from chick embryo telencephalons. J. Neurosci. Res 68 (2002) 424-431
33. Kontkanen O., and Castren E. Trophic effects of selegiline on cultured dopaminergic neurons. Brain Res. 829 (1999) 190-192
34. Lee H.K., Barbarosie M., Kameyama K., Bear M.F., and Huganir R.L. Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405 (2000) 955-959
35. Li X.M., Juorio A.V., Qi J., and Boulton A.A. l-deprenyl potentiates NGF-induced changes in superoxide dismutase mRNA in PC12 cells. J. Neurosci. Res. 53 (1998) 235-238
36. Loftis J.M., and Janowsky A. Regulation of NMDA receptor subunits and nitric oxide synthase expression during cocaine withdrawal. J. Neurochem. 75 (2000) 2040-2050
37. Loftis J.M., and Janowsky A. Cocaine treatment- and withdrawal-induced alterations in the expression and serine phosphorylation of the NR1 NMDA receptor subunit. Psychopharmacology 164 (2002) 349-359
38. Loftis J.M., and Janowsky A. The N-methyl-d-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 97 (2003) 55-85
39. Lu L., Grimm J.W., Hope B.T., and Shaham Y. Incubation of cocaine craving after withdrawal: a review of preclinical data. Neuropharmacology 47 Suppl. 1 (2004) 214-226
40. Maeda H., Sato T., and Maki S. Effects of dopamine agonists on hypothalamic defensive attack in cats. Physiol. Behav. 35 (1985) 89-92
41. Magyar K., Palfi M., Tabi T., Kalasz H., Szende B., and Szoko E. Pharmacological aspects of (-)-deprenyl. Curr. Med. Chem. 11 (2004) 2017-2031
42. Mann J.J., Aarons S.F., Wilner P.J., Keilp J.G., Sweeney J.A., Pearlstein T., Frances A.J., Kocsis J.H., and Brown R.P. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch. Gen. Psychiatry 46 (1989) 45-50
43. Maruyama W., Akao Y., Carrillo M.C., Kitani K., Youdium M.B., and Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24 (2002) 675-682
44. Melega W.P., Williams A.E., Schmitz D.A., DiStefano E.W., and Cho A.K. Pharmacokinetic and pharmacodynamic analysis of the actions of d-amphetamine and d-methamphetamine on the dopamine terminal. J. Pharmacol. Exp. Ther. 274 (1995) 90-96
45. Mizuta I., Ohta M., Ohta K., Nishimura M., Mizuta E., Hayashi K., and Kuno S. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Comm. 279 (2000) 751-755
46. Mori T., Ito S., Kita T., and Sawaguchi T. Effects of dopamine- and serotonin-related compounds on methamphetamine-induced self-injurious behavior in mice. J. Pharm. Sci. 96 (2004) 459-464
47. Moriguchi S., Watanabe S., Kita H., and Nakanishi H. Enhancement of N-methyl-d-aspartate receptor-mediated excitatory potentials in the neostriatum after methamphetamine sensitization. Exp. Brain Res. 144 (2002) 238-246
48. Nagy J., Horvath C., Farkas S., Kolok S., and Szombathelyi Z. NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurones. Neurochem. Int. 44 (2004) 17-23
49. Nakazawa T., Komai S., Tezuka T., Hisatsune C., Umemori H., Semba K., Mishina M., Manabe T., and Yamamoto C. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR2 (NR2B) subunit of the N-methyl-d-aspartate receptor. J. Biol. Chem. 276 (2001) 693-699
50. Nickel B., Szelenyi I., and Schulze G. Evaluation of physical dependence liability of l-deprenyl (selegiline) in animals. Clin. Pharmacol. Ther. 56 (1994) 757-767
51. Nishioku T., Shimazoe T., Yamamoto Y., Nakanishi H., and Watanabe S. Expression of long-term potentiation of the striatum in methamphetamine-sensitized rats. Neurosci. Lett. 268 (1999) 81-84
52. Nowakowska E., Kus K., Chodera A., and Rybakowski J. Investigating potential anxiolytic, antidepressant and memory enhancing activity of deprenyl. J. Physiol. Pharmacol. 52 (2001) 863-873
53. Ohmori T., Abekawa T., and Koyama T. The role of glutamate in behavioral and neurotoxic effects of methamphetamine. Neurochem. Int. 29 (1996) 301-307
54. Palmer M.R., Granholm A.C., van Horne C.G., Giardina K.E., Freund R.K., Moorhead J.W., and Gerhardt G.A. Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6-OHDA-lesioned rats. Brain Res. 890 (2001) 86-99
55. Palmer A.A., Verbitsky M., Suresh R., Kamens H.M., Reed C.L., Li N., Burkhart-Kasch S., McKinnon C.S., Belknap J.K., Gilliam T.C., and Phillips T.J. Gene expression differences in mice divergently selected for methamphetamine sensitivity. Mamm. Genome 16 (2005) 291-305
56. Paterson I.A., and Tatton W.G. Antiapoptotic actions of monoamine oxidase B inhibitors. Adv. Pharmacol. 42 (1998) 312-315
57. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, San Diego
58. Riddle E.L., Kokoshka J.M., Wilkins D.G., Hanson G.R., and Fleckenstein A.E. Tolerance to the neurotoxic effects of methamphetamine in young rats. Eur. J. Pharmacol. 435 (2002) 181-185
59. Riviere G.J., Byrnes K.A., Gentry W.B., and Owens S.M. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J. Pharmacol. Exp. Ther. 291 (1999) 1220-1226
60. Robbins T. Chemistry of the mind: neurochemical modulation of prefrontal cortical function. J. Comp. Neurol. 493 (2005) 140-146
61. Roche K.W., O'Brien R.J., Mammen A.L., Bernhardt J., and Huganir R.L. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16 (1996) 1179-1188
62. Schiffer W.K., Azmoodeh M., Gerasimov M., Volkow N.D., Fowler J.S., and Dewey S.L. Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine. Synapse 48 (2003) 35-38
63. Schneider L.S., Tariot P.N., and Goldstein B. Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin. Pharmacol. Ther. 56 (1994) 750-756
64. Seeburg P.H. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci. 16 (1993) 359-365
65. Segal D.S., Kuczenski K., O'Neil M.L., Melega W.P., and Cho A.K. Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28 (2003) 1730-1740
66. Semkova I., Wolz P., Schilling M., and Krieglstein J. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur. J. Pharmacol. 315 (1996) 19-30
67. Shappell S.A., Kearns G.L., Valentine J.L., Neri D.F., and DeJohn C.A. Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man. J. Clin. Pharmacol. 36 (1996) 1051-1063
68. Shimazu S., Tanigawa A., Sato N., Yoneda F., Hayashi K., and Knoll J. Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes. Life Sci. 72 (2003) 2785-2792
69. Shintomi K. Effects of psychotropic drugs on methamphetamine-induced behavioral excitation in grouped mice. Eur. J. Pharmacol. 31 (1975) 195-206
70. Sivenius J., Sarasoja T., Aaltonen H., Heinonen E., Kilkku O., and Reinikainen K. Selegiline treatment facilitates recovery after stroke. Neurorehab. Neur. Rep. 15 (2001) 183-190
71. Snyder G.L., Allen P.B., Fienberg A.A., Valle C.G., Huganir R.L., Nairn A.C., and Greengard P. Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. J. Neurosci. 20 (2000) 4480-4488
72. Sonsalla P.K., Jochnowitz M.D., Zeevalk G.D., Oostveen J.A., and Hall E.D. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 738 (1996) 172-175
73. Stephens S.E., and Yamamoto B.K. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 17 (1994) 203-209
74. Sun W., Zhao Y., and Wolf M.E. Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J. Neurosci. 25 (2005) 7342-7351
75. Takahata K., Katsuki H., Kobayashi Y., Muraoka S., Yoneda F., Kume T., Kashii S., Honda Y., and Akaike A. Protective effects of selegiline and desmethylselegiline against N-methyl-d-aspartate-induced rat retinal damage. Eur. J. Pharmacol. 458 (2003) 81-89
76. Tang Y.P., Ma Y.L., Chao C.C., Chen K.Y., and Lee E.H. Enhanced glial cell line derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments. J. Neurosci. Res. 53 (1998) 593-604
77. Themann C., Alvarez Fischer D., Gross S., Westermann R., Weihe E., Kuschinsky K., Schafer H., and Ferger B. Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels. Naunyn-Schmiedeberg's Arch. Pharmacol. 365 (2002) 22-28
78. Thornton C., Dore C.J., Elsworth J.D., Herbert M., and Stern G.M. The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacology 70 (1980) 163-166
79. ThyagaRajan S., Stevens S.Y., and Felten D.L. Region-specific alterations in the concentrations of catecholamines and indoleamines in the brains of young and old F344 rats after l-deprenyl treatment. Brain Res. Bull. 48 (1999) 513-520
80. Ungless M.A., Whistler J.L., Malenka R.C., and Bonci A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 411 (2001) 583-587
81. Vezina P., Mohr E., and Grimes D. Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects. Can. J. Neurol. Sci. 19 (1992) 142-146
82. Volkow N.D., Fowler J.S., Wolf A.P., and Gillespi H. Metabolic studies of drugs of abuse. NIDA Res. Monogr 105 (1991) 47-53
83. Winger G.D., Yasar S., Negus S.S., and Goldberg S.R. Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys. Clin. Pharmacol. Ther. 56 (1994) 774-780
84. Xu L., Ma J., Seigel G.M., and Ma J.X. l-Deprenyl, blocking apoptosis and regulating gene expression in cultured retinal neurons. Biochem. Pharmacol. 58 (1999) 1183-1190
85. Zhang Y., Loonam T.M., Noailles P.A., and Angulo J.A. Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions. Ann. N.Y. Acad. Sci. 937 (2001) 93-120
86. Zhang X., Lee T.H., Davidson C., Lazarus C., Wetsel W.C., and Ellinwood E.H. Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors. Neuropsychopharmacology (2006) 10.1038/sj.npp.1301101 advance online publication
87. Zhao M.G., Toyoda H., Lee Y.S., Wu L.J., Ko S.W., Zhang X.H., Jia Y., Shum F., Xu H., Li B.M., Kaang B.K., and Zhuo M. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron 47 (2005) 859-872